Alopecia (Hair Loss)

Researchers are evaluating the use of a non-ablative 1470 nm laser to treat androgenetic alopecia and scarring alopecia in adults. This pilot study is open-label, baseline-controlled, and conducted at a single center. The study includes participants with biopsy-proven alopecia who have experienced stable hair loss for at least six months. The goal is to explore the laser's effects on hair loss improvement, as it has not yet been tested for these conditions despite FDA clearance for dermatologic use. Participants will be divided into two groups, each with five people: one group for androgenetic alopecia and one for scarring alopecia. Each subject may receive up to three laser treatments targeting multiple areas of the scalp. Treatments last about 10 to 15 minutes and follow a protocol that includes topical anesthetic and antiseptic cleaning before the laser application. Post-treatment care includes applying a topical steroid cream. Follow-up visits are scheduled at months 6, 9, 12, and 15 to monitor progress. Throughout the study, researchers will conduct clinical assessments including standardized photography and hair density measurements using the Canfield HairMetrix® device. Participants will complete questionnaires to report pain levels, hair growth self-assessments, and any adverse events. Primary outcomes include live and photographic assessments of hair loss, hair density, and hair counts at multiple timepoints up to month 15. Subject satisfaction will also be tracked. The study duration allows careful monitoring of changes and safety over more than a year.

Researchers are evaluating the effects of traditional Chinese herbal products on hair loss (alopecia) and gray hair (canities) in adults aged 18 to 60 years. This 6-month randomized, double-blind, placebo-controlled trial will enroll 152 participants, including some with gray hair, to study changes in hair count, density, and color. The trial aims to better understand how oral capsules and topical hair tonics may impact hair health. Participants will be randomly assigned to one of four groups, each receiving a combination of oral capsules and hair tonic or placebos for 24 weeks. The groups include VitaGreen Capsule A plus VitaGreen Tonic, VitaGreen Capsule B plus VitaGreen Tonic, Capsule Placebo plus VitaGreen Tonic, and Capsule Placebo plus Tonic Placebo. Treatments will be used as directed throughout the 24-week period. During the study, participants will attend three in-person visits at baseline, week 12, and week 24. Hair-related assessments include hair shedding counts, local hair counts, hair density, and photographic scoring of hair changes. A subset of participants with gray hair will have additional evaluations of hair color changes. Blood tests, urinalysis, and safety monitoring for adverse events will also be conducted. All clinical data will be collected for analysis, with the total participation lasting about six months.

This clinical trial focuses on adults aged 22 to 70 with androgenic alopecia, also known as male or female pattern hair loss. It aims to evaluate how well the Ultra device works and how safe it is for promoting hair regrowth by measuring improvements in hair density and hair shaft thickness. The study is sponsored by CynosureLutronic and involves no masking or blinding. Participants will receive six treatments using the Ultra device, which employs low level laser therapy on the scalp. These treatments are spaced about two weeks apart, with a small allowance of plus or minus three days. The study tracks changes from the start of treatment through to a 90-day follow-up after the final treatment. During the study, participants will be monitored for changes in hair density compared to their baseline levels. They will need to avoid significant hair changes like drastic haircuts or coloring and maintain their usual diet and exercise routines. The study requires adherence to visit schedules and restrictions on other hair growth treatments or medications. Safety and treatment effects are observed throughout the study period, which ends in December 2026.

Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with lichen planopilaris, a condition affecting the scalp. This Phase 2/3 randomized, double-blind, placebo-controlled study aims to understand how well this drug works compared to a placebo in improving symptoms of this condition. The trial is sponsored by Priovant Therapeutics, Inc. and focuses on finding treatments that may help reduce disease activity and symptoms. Participants will be randomly assigned to receive either oral brepocitinib or a placebo. The study will monitor their progress over 24 weeks, measuring changes using the Investigator's Global Assessment (IGA) score and symptom rating scales. The trial includes a treatment period where participants take the oral medication and are regularly assessed for response and safety. Throughout the study, participants will have clinical evaluations to track their scalp condition and symptom changes. The main outcome measured is the proportion of participants achieving a significant improvement in IGA score by week 24. Secondary outcomes include changes in symptom severity. Safety will be closely monitored, and the total duration of participation will cover the treatment and follow-up periods up to week 24.

Central centrifugal cicatricial alopecia (CCCA) is a type of scarring hair loss mainly affecting middle-aged women of African descent. This condition causes patches of scarred scalp that grow larger over time, leading to brittle, shorter hair and symptoms like itching, pain, and tenderness. Since CCCA can cause permanent hair loss and distress, effective treatments are needed, but current options are limited and not well studied. This study evaluates the Revian Red All LED cap, a wireless device that uses two wavelengths of light (620 nm and 660 nm) once daily for 10 minutes, to see if it can reduce inflammation, stop hair loss, and encourage regrowth in people with CCCA. Five women diagnosed with CCCA will use the cap daily for six months. Photos and dermatoscope images will be taken every two months to track changes in hairline and hair growth. Participants will complete questionnaires about their hair loss symptoms at each visit. The study measures include hairline stabilization and regrowth at multiple time points over six months. The research team aims to assess if this light therapy can help manage CCCA symptoms and hair loss. The entire study lasts six months, with ongoing monitoring and symptom evaluation during that time.

Researchers are studying the impact and burden of three skin conditions: moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given; instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

Researchers are evaluating the safety and effectiveness of baricitinib for treating severe or very severe alopecia areata, a condition causing hair loss, in children aged 6 to less than 18 years. This Phase 3 clinical trial aims to determine how well baricitinib works in this young population, with careful monitoring of outcomes related to hair regrowth and patient well-being. Participants will be randomly assigned to one of three groups: a high dose of baricitinib, a low dose of baricitinib, or a placebo. The study includes four periods: a 5-week screening phase to determine eligibility, a 36-week double-blind treatment period where participants receive their assigned treatment, an approximately 2-year long-term extension to observe longer-term effects, and a 4-week follow-up after treatment ends. Some participants may continue to receive treatment after the extension for up to 180 weeks. During the trial, children will undergo regular assessments including the Severity of Alopecia Tool (SALT) score to measure hair loss, patient-reported outcomes on scalp hair, eyebrow, and eyelash hair, as well as evaluations of anxiety, depression, and quality of life. Blood tests will monitor drug levels and immune response. Participants will be closely followed throughout the study periods to track changes and ensure safety, with the total participation lasting over two years depending on extension eligibility.

Researchers are evaluating the effects of LAD603 in adults aged 18 to 65 with severe to very severe alopecia areata (AA), a condition causing significant scalp hair loss. This Phase 2, randomized, placebo-controlled, and double-blind study aims to assess the efficacy of LAD603 on hair loss severity, as well as its safety, how the body processes the drug (pharmacokinetics), immune response to the drug (immunogenicity), and related biomarkers. Participants will be randomly assigned to receive one of three different doses of LAD603 or a placebo. Each treatment involves subcutaneous injections administered from Day 1 through Week 28. The study includes four groups: LAD603 Dose A, Dose B, Dose C, and a placebo group. Treatments are given regularly during this 28-week period to monitor effects and safety. During the study, participants will have their hair loss severity measured using the Severity of Alopecia Tool (SALT) score at baseline and Week 28. Additional assessments include clinician-reported outcomes for eyelash and eyebrow hair loss at Week 28. Researchers will monitor safety, side effects, and immune responses throughout the 28 weeks. Participation involves regular visits for injections, assessments, and laboratory tests to collect relevant data on LAD603's impact and safety.

Researchers are evaluating how well LY4005130 works for adults with severe alopecia areata, a condition causing significant hair loss. This Phase 2 study compares LY4005130 with a placebo to assess its effects, how well participants tolerate it, and possible side effects. Blood tests will be used to understand how the body processes the drug and how the drug affects the body. Participants will receive either LY4005130 or a placebo through an intravenous (IV) infusion into a vein in the arm. The study is randomized, double-blind, and placebo-controlled to ensure unbiased results. The treatment period and overall study duration last about 48 weeks, including screening time. During the study, participants will undergo regular assessments including the Severity of Alopecia Tool (SALT) to measure hair loss improvement. Researchers will also monitor drug levels in the blood and changes in gene expression from scalp biopsies. The primary outcome is the percentage of participants achieving a SALT score of 20 or less by week 24. Safety and tolerability will be closely observed throughout the study.

Researchers are evaluating the use of human umbilical cord mesenchymal stem cell exosomes (hUCMSC-sEV) for treating androgenic alopecia, a common form of hair loss, in young men aged 18 to 35. This clinical trial aims to determine whether hUCMSC-sEV are effective and safe for this purpose. The study includes two phases: a dose-finding Phase I and a randomized controlled Phase II comparing hUCMSC-sEV with minoxidil, a current hair loss treatment. In Phase I, participants receive injections of hUCMSC-sEV at three different dose levels, adjusted to the area of hair loss, with treatments given at weeks 0, 2, 4, and 6, followed by follow-up visits at weeks 8, 12, and 24. Phase II involves randomly assigning participants to either receive the optimal dose of hUCMSC-sEV injections at the same schedule or daily topical minoxidil applied for 12 weeks, with follow-up visits also at weeks 8, 12, and 24. Participants will attend clinic visits for treatments and assessments including measurements of hair density, hair diameter, and hair count from the first treatment up to 24 weeks. The trial monitors safety, tolerability, and hair growth outcomes over the study period. The total participation time spans approximately 24 weeks from initial treatment through follow-up assessments.